Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Effect of Forex Changes
Change in reported cash caused by exchange-rate movements on foreign-currency balances.
Immunocore Holdings plcNASDAQ: IMCR
Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026
Effect of forex changes turns negative
Q1 FY2026 effect of forex changes was -$6.15M, compared with $8.43M a year earlier. Trailing-twelve-month effect of forex changes was $12.08M.
Context
- Effect of forex changes amounted to 6.7% of revenue in FY2025, up 6.0 pp from a year earlier.
- Effect of forex changes increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly effect of forex changes holds near -$6.15M or moves back toward the trailing-twelve-month quarterly average of $3.02M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Effect of Forex Changes history
Mixed currencies · from the cash flow
- Latest · FY2025
- 19.81M USD
- Year-over-year change
- +1259.9%
| Period | Period end | Effect of Forex Changes | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.81M | +1259.9% |
| FY2024 | 2024-12-31 | (1.71M) | — |
| FY2023 | 2023-12-31 | 6.56M | +151.9% |
| FY2022 | 2022-12-31 | (12.65M) | -2123.4% |
| FY2021 | 2021-12-31 | 625K | — |
Effect of Forex Changes vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +66.1% is the 4th highest of 7, against a peer median of +399.0%.
- Effect of forex changes amounts to 3.1% of revenue for IMCR, versus a peer median of 7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €366.99M EUR | -133.8% | +159.7% | 13.9% | |
| LTM Dec 2025 | $83.14M USD | — | — | 114.3% | |
| LTM Mar 2026 | $12.08M USD | +66.1% | — | 3.1% | |
| LTM Mar 2026 | €11.53M EUR | +7148.8% | +123.9% | 30.9% | |
| FY2025 | €7.41M EUR | +1566.4% | — | 265.7% | |
| FY2025 | A$6.73M AUD | +795.0% | — | 133.4% | |
| LTM Sep 2026 | $299K USD | -10066.7% | -62.5% | 0.2% | |
| LTM Jun 2026 | $103K USD | +3.0% | — | 0.1% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding IMCR) | — | +399.0% | +123.9% | 7.0% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.